🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for BRCA1/2

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. NCT07356453Phase 18 sites📍 Palo Alto📍 San Francisco📍 Grand Rapids FoRx Therapeutics AG · Tests: FORX-428 PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384Phase 31 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Ca… Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314Phase 3695 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation NCT05806515Phase 2133 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners NCT06111417n/a2 sites📍 Dijon📍 Levallois-Perret Centre Georges Francois Leclerc · Tests: Questionnaires, Communication of the results of the BRCA1/2 ultra rapid test Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) NCT04520074Phase 31 site📍 Shanghai Fudan University · Tests: Etoposide, Cyclophosphamide, Carboplatin/Cisplatin A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance NCT07321015Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Fluzoparib Monotherapy Study of How People Make Decisions About Prostate Cancer Risk NCT07197723n/a1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: cheek (buccal) swab, Assessments, optional collection of blood Patient Experiences After Risk-Reducing Mastectomy Among Women Carrying BRCA1/2 Pathogenic Variants Without a Diagnosis of Breast Cancer NCT07821593n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer NCT06201234Phase 236 sites📍 Stuttgart📍 Tübingen📍 Winnenden GBG Forschungs GmbH · Tests: Olaparib + Elacestrant, Olaparib CfDNA in Hereditary And High-risk Malignancies 2 NCT06726642n/a8 sites📍 Vancouver📍 St. John's📍 Halifax University Health Network, Toronto · Tests: Cell-free DNA analysis Identifying and Caring for Individuals With Inherited Cancer Syndrome NCT04494945NA2 sites📍 Portland📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer NCT04251052NA574 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging,… The Cancer of the Pancreas Screening-5 CAPS5)Study NCT02000089Phase 39 sites📍 New Haven📍 Baltimore📍 Boston Johns Hopkins University · Tests: Secretin, MRI, Tumor marker gene test with CA19-9 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer NCT06488378Phase 12 sites📍 Boston📍 Rochester Dana-Farber Cancer Institute · Tests: Axatilimab, Olaparib Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766Phase 23 sites📍 Gifu📍 Okayama📍 Tokyo Okayama University · Tests: Pembrolizumab, Paclitaxel, Carboplatin, Olaparib, Definitive Surgery Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene NCT06817694NA1 site📍 Québec CHU de Quebec-Universite Laval · Tests: Cognitive-behavioral group therapy Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes NCT03396341n/a7 sites📍 Boston📍 Basking Ridge📍 Commack Memorial Sloan Kettering Cancer Center · Tests: Salvia sample, Questionnaires, Buccal swab sample Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer NCT06775470n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna · Tests: Patients must have been diagnosed with ovarian cancer and be BRCA positive, BRCA1 and BRCA2 positive, and be affected b… Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751Phase 3306 sites📍 Gilbert📍 Fountain Valley📍 Glendale AstraZeneca · Tests: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib Pancreatic Cancer Genetics NCT01102569n/a1 site📍 New York Columbia University A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer NCT07532434n/a1 site📍 Beijing Peking University Third Hospital Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk NCT02478892n/a1 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen, Blood sample collection for research Men at High Genetic Risk for Prostate Cancer NCT03805919n/a1 site📍 Bethesda National Cancer Institute (NCI) Pancreatic Cancer Screening for At-risk Individuals NCT05006131n/a1 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Screening for pancreatic cancer Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT07156253Phase 12 sites📍 Shanghai📍 Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Tests: SYN818 and Olaparib will be administered A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) NCT07292246NA1 site📍 Glyfada Vasileios Kalles · Tests: Endoscopic nipple sparing mastectomy, HandX endoscopic instrument
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy